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Abstract
Background: Sphingosine-1-phosophate (S1P) is a biologically active sphingolipid metabolite that influences
cellular events including differentiation, proliferation, and migration. S1P acts through five distinct cell surface
receptors designated S1P1-5R, with S1P1R having the highest expression level in the developing heart. S1P1Ri s
critical for vascular maturation, with its loss leading to embryonic death by E14.5; however, its function during early
cardiac development is not well known. Our previous studies demonstrated that altered S1P levels adversely affects
atrioventricular (AV) canal development in vitro, with reduced levels leading to cell death and elevated levels
inhibiting cell migration and endothelial to mesenchymal cell transformation (EMT).
Results: We determined, by real-time PCR analysis, that S1P1R was expressed at least 10-fold higher than other S1P
receptors in the developing heart. Immunohistochemical analysis revealed S1P1R protein expression in both
endothelial and myocardial cells in the developing atrium and ventricle. Using AV canal cultures, we observed that
treatment with either FTY720 (an S1P1,3,4,5R agonist) or KRP203 (an S1P1R-specific agonist) caused similar effects on
AV canal cultures as S1P treatment, including induction of cell rounding, inhibition of cell migration, and inhibition
of EMT. In vivo, morphological analysis of embryonic hearts at E10.5 revealed that S1P1R-/- hearts were malformed
with reduced myocardial tissue. In addition to reduced myocardial tissue, E12.5 S1P1R-/- hearts had disrupted
morphology of the heart wall and trabeculae, with thickened and disorganized outer compact layer and reduced
fibronectin (FN) deposition compared to S1P1R+/+ littermates. The reduced myocardium was accompanied by a
decrease in cell proliferation but not an increase in apoptosis.
Conclusions: These data indicate that S1P1R is the primary mediator of S1P action in AV canal cultures and that
loss of S1P1R expression in vivo leads to malformed embryonic hearts, in part due to reduced fibronectin
expression and reduced cell proliferation.
Background
Sphingosine-1-phosphate (S1P) is a biologically active
lysophospholipid that is involved in cellular differentia-
tion, proliferation, migration, cytoskeletal reorganization,
and apoptosis [1,2]. S1P is produced by sphingosine
k i n a s e1a n d2( S P H K 1a n dS P H K 2 )f r o ms p h i n g o s i n e
in response to various cellular stimuli, including vascular
endothelial growth factor (VEGF), platelet-derived
growth factor (PDGF), tumor necrosis factor-a (TNFa),
transforming growth factor-beta (TGFb), epidermal
growth factor (EGF) and cytokines [1-5]. After release
from cells, S1P acts in an autocrine and paracrine
manner through its cell surface receptors to influence
cellular processes.
S1P receptors (S1PRs) are G protein-coupled receptors
(GPCRs) critical for S1P action; five subtypes have been
described S1P1-5R (formerly Edg1, Edg5, Edg3, Edg6, and
Edg8, respectively)[6,7]. Three S1P receptor subtypes
(S1P1,2,3R) are expressed in the adult cardiovascular sys-
tem, each with a unique pattern of expression [8,9]. S1P1R
is strongly expressed in cardiomyocytes and vascular
endothelium [8]. S1P2R is the dominate receptor in vascu-
lar smooth muscle cells [8]. S1P3R is highly expressed in
cardiac fibroblasts [8].
In the developing embryo, S1P1,2,3,4R expression is
detected in the murine heart from embryonic days (E)
8.5-12.5 by reverse transcriptase (RT) PCR [10]. S1P5R
expression is not detected in the developing heart by
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any medium, provided the original work is properly cited.either RT-PCR or in situ hybridization [10,11]. S1P1Ri s
the only S1P receptor detected in the heart from E8.5 to
E12.5 by in situ hybridization [11]. S1P1R is exclusively
expressed in the heart at E8.5-E9.5 and is strongly
expressed in the heart and developing vasculature
throughout the embryo from E10.5-12.5, as well as
other tissues including branchial arches, limb buds, and
brain [11].
S1P action is implicated in the regulation of numerous
cardiovascular processes including angiogenesis, vascular
permeability, arteriogenesis, cardiac function, vascular
development, and vascular tone [9,12,13]. In fish, dele-
tion of S1P2Rs (miles apart) results in cardia bifida,
which is caused by a failure of the myocardial precursor
cells to migrate to the ventral midline of the embryo
and fuse to form the heart tube [14].
In mice, deletion of S1P1R causes embryonic death
between E13.5 and E14.5 due to defects in vascular
maturation [15]. In S1P1R-/- embryos, the failure of vas-
cular smooth muscle cells (VSMC) to surround and sup-
port the developing vasculature results in massive
hemorrhaging [15,16]. The bleeding observed in S1P1R-/-
embryos results from a loss of receptor expression speci-
fically in the endothelium [15,16]. The loss of S1P2Ro r
S1P3R individually have no adverse affects on cardiovas-
cular development in mice, and null animals are viable
[17]. However, loss of both S1P2Ra n dS 1 P 3R leads to
reduced viability after E13.5, possibly due to abnormal
endothelium formation in microvessels [18-20]. Although
an important role for S1P in vascular development has
been observed [15], our understanding of the role of S1P
during cardiac development is limited.
Disruptions in cardiac cushion tissue development can
lead to septation and valve defects in the heart, which are
among the most common congenital heart malforma-
tions observed in humans [21,22]. A major component of
cardiac cushion development is the transformation of
endothelial cells into mesenchymal cells that invade the
cushion tissue and contribute to the formation of mature
heart valves [23,24]. Some signaling molecules, including
TGFb and VEGF, that are involved in promoting and
inhibiting endothelial to mesenchymal cell transforma-
tion (EMT) in the heart can also regulate S1P production
by influencing SPHK [4,5,25-28].
We demonstrated that altered S1P signaling disrupts
cell morphology and cell survival in cardiac cushion tis-
sue [10]. Elevated S1P levels lead to changes in the actin
cytoskeleton and cell rounding [10]. In addition, S1P
inhibits cell migration and prevents endothelial to
mesenchymal cell transformation (EMT) in atrioventricu-
lar (AV) canal cushions [10]. In contrast, reducing S1P
synthesis by treating with N, N-dimethylsphingosine
(DMS), an inhibitor of SPHK, causes apoptosis of myo-
cardial and endocardial cells in AV canal cushions [10].
We now identify S1P1Rs as the primary mediators of
S1P action in cardiac cushion tissue, and demonstrate
that loss of S1P1Rs disrupts cardiac development, in
part by reducing cell proliferation and reducing FN
expression in the heart.
Results and Discussion
S1P1R is the most highly expressed S1P receptor in the
developing heart
To assess relative expression levels of S1P receptors, we
performed quantitative real-time PCR analysis with
RNA isolated from embryonic hearts at E9.5, the begin-
ning of cardiac cushion development, and at E12.5, a
late stage of cardiac cushion development. Please note
that specific radiolabeled ligands are not available to
directly characterize receptor binding site expression.
Real-time PCR revealed that S1P1R is the predominate
S1P receptor expressed in E9.5 and E12.5 embryonic
hearts and that S1P2R, S1P3R, and S1P4R are expressed
at very low levels compared to S1P1R( F i g u r e1 ) .U s i n g
mean normalized expression methods to analyze real-
time PCR results, it was observed that S1P1Rw a s
expressed at greater than 10-fold higher levels than
other S1P receptor subtypes in the developing heart,
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Figure 1 S1P1R is the highest expressed S1P receptor in the
developing heart. Real-time PCR analysis was performed on RNA
samples isolated from either hearts only or embryos with hearts
removed at (A) E9.5 and (B) E12.5. S1P receptor gene expression
was compared to b-actin expression to determine the mean
normalized expression. Each analysis was performed in triplicate.
Poulsen et al. BMC Developmental Biology 2011, 11:37
http://www.biomedcentral.com/1471-213X/11/37
Page 2 of 12a n dt h a tS 1 P 1R gene expression in the rest of the
embryo was low compared to the heart at these early
embryonic stages (Figure 1).
To localize the expression of S1P1R at the cellular
level, we performed immunohistochemical analysis with
an antibody against S1P1R. S1P1R protein was localized
to cardiomyocytes and endothelial cells in the heart at
E10.5 and E12.5 (Figure 2). Myocardium of both the
ventricle and atrium expressed S1P1R protein at E10.5
and E12.5 (Figure 2). In addition, S1P1Rp r o t e i nw a s
detected in vascular endothelial cells throughout the
embryo (Figure 2). These patterns of S1P1R expression
are similar to that observed in the adult [8]. These data
show that S1P1Rs are the primary receptor subtype
expressed in the early developing murine heart.
As detailed above, we demonstrate that S1P1Ri s
highly expressed from E9.5 to E12.5, stages that span an
important developmental period for the heart. During
these stages, there is expansion of the cardiac cushions
and the beginning of their refinement into cardiac valves
[29]. In addition, the myocardium undergoes differentia-
tion and development of the compact outer layer of the
heart as well as formation of trabeculae [30]. Our gene
expression results were consistent with in situ hybridiza-
tion analysis [11], which demonstrated that of the five
S1P receptor subtypes, only S1P1R was detected in the
developing heart at the stages we examined. Here, we
expand on earlier analysis and demonstrate that S1P1Rs
are expressed at the protein level in both myocardial
and endocardial cells during early heart development.
Taken together these data indicate that S1P1Ri s
expressed at the right time and in the right cells to
influence multiple aspects of cardiac development.
S1P1R mediates effects of S1P treatment on AV canal
cultures
To identify the S1P receptor subtype(s) that mediate
S1P action, agonists and antagonists to specific S1P
receptors were applied to AV canals grown in culture.
The doses used were previously validated to either block
or activate specific S1P receptors [31-33].
FTY720, an agonist for S1P1,3,4,5 when converted to
FTY720-P by SPHK2, caused similar effects on AV canal
cultures as S1P in a dose-dependent manner (Figure 3).
Treatment of AV canals with 0.5 μMF T Y 7 2 0i n h i b i t e d
cellular outgrowth from the explants by 15%, and inhib-
ited EMT by 72%. Treatment with 1.0 μM FTY720
caused a 40% decrease in cellular outgrowth and a 79%
inhibition of EMT (Figure 3). These two doses of
FTY720 induced changes in cell morphology, including
cell rounding and actin cortical stress fiber formation
(Figure 3). This cellular phenotype was in contrast to the
fusiform shape of vehicle-treated cells that have many
cellular processes extending from the cell body, indicat-
ing cellular migration over the surface of the collagen gel
(Figure 3). At the highest dose of 2.5 μM, FTY720 com-
pletely inhibited cell migration and EMT (Figure 3). In
addition, 2.5 μM FTY720 treatment caused explant
death, as measured by beating. Only 42% (N = 12) of
2.5 μM FTY720-treated explants were still beating and
alive at the end of 48 hours of incubation, compared to
100% for vehicle (N = 39), 0.5 μM FTY720 (N = 9), or
1.0 μM FTY720 (N = 33) treated explants.
We next tested the S1P1R-specific agonist KRP203
[34]. KRP203 inhibited cellular outgrowth and EMT in a
dose-dependent manner. Treatment with 0.25 μM
KRP203 inhibited outgrowth from the AV canal explants
by 33.9% and blocked EMT by 33.3% (Figure 3). 0.5 μM
KRP203 inhibited cellular outgrowth by 52.6% and
Figure 2 S1P1R protein is localized to myocardial and
endocardial cells in the developing heart. Wild type C57Bl/6
embryo sections were immunostained with (A, C, E) control normal
rabbit IgG or (B, D, F) a rabbit polyclonal antibody against S1P1R. A
secondary antibody conjugated to hydrogen peroxidase was used
in conjunction with a Vector SG substrate color reaction kit to
produce a blue-grey precipitate wherever S1P1R was expressed.
Sections were counterstained with nuclear fast red to label the
nuclei in each cell. S1P1R expression was observed in the
myocardium (M) of both the atrium (At) and ventricle (V) as well as
in endothelial cells (arrows) in both (A, B) E10.5 and (C, D) E12.5
hearts. (E, F) E10.5 embryonic sections, at the level of the somites,
depicting vascular endothelial cells (arrow heads) stained with anti-
S1P1R antibodies. (A, B, C, D) Scale bar = 100 μm, (A and B inserts
and E, F) scale bar = 50 μm.
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Page 3 of 12Figure 3 S1P1R mediates cell rounding, cellular outgrowth, and EMT in AV canal cultures. AV canals were explanted at E9.5 and treated at
2 and 24 hours with vehicle or S1P receptor agonists or antagonists. Explants were stained with phalloidin conjugated to Alexa Fluor 488. (A)
Vehicle treated explants show normal cellular outgrowth and elongated cell morphology. (B) S1P (2.5 μM) treatment causes reduced outgrowth
and cell rounding. (C) CAY10444 (2.5 μM), an S1P3R antagonist, treated cultures have normal cellular outgrowth and cell morphology. (D)
CAY10444 (2.5 μM) is unable to rescue explants from S1P (2.5 μM) treatment, as these cultures have inhibited cell migration and rounded cells.
(E) The S1P1R specific agonist, KRP203 (0.5 μM) causes reduced cellular outgrowth and cell rounding similar to S1P treatment. (F) FTY720 (1.0
μM), an S1P1,3,4,5R agonist also causes reduced cellular outgrowth and cell rounding similar to S1P. (G) The average cellular outgrowth for each
treatment was calculated and displayed as a percent of the vehicle control cellular outgrowth. (H) Each explant was examined for transformed
mesenchymal cells that had invaded into the collagen gel. An explant was scored as inhibited if less than 5 mesenchymal cells had invaded.
Results are displayed as a percent of explants that were inhibited. Vehicle control and CAY10444 showed no inhibition, while the other
treatments had significant inhibition of mesenchymal cell formation. Scale bar low magnification equals 200 μm, and in high magnification
inserts it equals 50 μm. N equals number of explants measured. *P ≤ 6.3 × 10
-5, **P ≤ 0.0005.
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Page 4 of 12inhibited EMT by 88.8% in AV canal cultures (Figure 3).
KRP203 caused changes in cell morphology, similar to
S1P and FTY720 treatment, which included cell round-
ing, fewer filapodia extending from the cells, and the
formation of actin stress fibers (Figure 3). At a higher
dose of 2.5 μM, KRP203 inhibited outgrowth by 74.2%
and completely blocked EMT (Figure 3). As with the
highest dose of FTY720, 2.5 μM KRP203 caused AV
canal explant death. Only 33.3% (N = 8) of 2.5 μM
KRP203-treated explants were alive and beating after 48
hours as compared to 100% of explants treated either
with vehicle (N = 21) or 0.5 μM KRP203 (N = 12).
Since higher doses of FTY720 and KRP203 caused
explant death, we tested whether the lower doses of
FTY720 (1.0 μM) and KRP203 (0.5 μM) caused an
increase in cell death in either endothelial cells or cardio-
myocytes of AV canal explants, without causing complete
explant death. Using a cell viability assay, we determined
that S1PR agonist treatment affects cell morphology and
cell migration independent of cell toxicity. The calcein
AM (green, live cells) staining clearly marked the majority
of the muscle cells in the explant and numerous endothe-
lial cells on the collagen gel surface, regardless of treat-
ment (Figure 4). The ethidium homodimer-1 (red, dead
cells) staining showed minimal dead cells in the muscle
explant and some dead cells on the surface of the gel with
each treatment (Figure 4). However, it did not appear that
either FTY720 (1.0 μM) or KRP203 (0.5 μM) treatment
increased cell death significantly above what was observed
in vehicle-treated cultures (Figure 4).
Another S1P receptor expressed in adult cardiac tissue
is S1P3R [35]. Although the level of S1P3R expression in
the developing heart was much lower than S1P1Ri no u r
real-time PCR experiments, we tested whether it could
mediate S1P effects in our AV canal cultures. We treated
cultures with CAY10444, a specific S1P3Ra n t a g o n i s t
[33]. CAY10444 (2.5 μM) treatment alone had no adverse
effects on the AV canal cultures (Figure 3). Pretreatment
of AV canal cultures with CAY10444 was unable to pre-
vent cell rounding or inhibition of cellular outgrowth
caused by S1P treatment (Figure 3).
As we reported, S1P action can directly effect cardiac
development and differentiation in an in vitro culture
system [10]. In our current studies, we used agonists and
antagonists to specific S1P receptors to determine which
receptor subtype mediates S1P action in the developing
heart. The S1P1R specific agonist (KRP 203) had similar
effects on cell morphology and migration as S1P, which
indicates that S1P1Rs are the critical S1P receptors in the
embryonic heart. FTY720 does not bind S1P2Rs [31,36],
thus we can eliminate S1P2Rs as the predominate media-
tors of S1P signaling in AV canals because FTY720 treat-
ment leads to similar changes in cell motility and
morphology as S1P. S1P3Rs do not appear to be the
Figure 4 S1P receptor agonists do not increase cell death in AV canal cultures. Cell viability was assessed following S1P1R receptor agonist
treatment. (A, D) AV canal explant treated with vehicle control (methanol). (B, E) explants treated with 0.5 μM KRP203. (C, F) explants treated with
1.0 μM FTY720. (A, B, C) only live cells are labeled with calcein AM and appear green, where as (D, E, F) only dead cells are labeled with
ethidium homodimer-1 and appear red. Dead cells are seen around the edges of the explants and in the muscle explants but the majorities of
cells fluoresce green and are alive under all treatments. Scale bar = 200 μm.
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Page 5 of 12primary mediators of S1P action either since an S1P3R-
specific antagonist could not prevent S1P from inhibiting
cell migration and EMT. S1P4R is only minimally
expressed in the heart as detected by RT-PCR, and S1P5R
is not at all expressed in the heart, as previously reported
[10], both of which suggest that they are not critical for
S1P action in the AV canals. Taken together, these data
indicate that S1P1Rs are the primary mediators of S1P
action in cardiac cushion tissue. These experiments, how-
ever, do not eliminate the possibility that other receptors
like S1P2Ra n dS 1 P 3R, both of which have a low level of
expression in the embryonic heart, could also mediate
S1P signaling in the developing heart, especially if S1P1R
expression is lost. The notion that S1P receptor subtypes
can compensate for the loss of other subtypes in the car-
diovascular system is supported by data showing that
gene knockout of multiple S1P receptor subtypes leads to
more severe phenotypes and younger embryonic lethality
[20].
Loss of S1P1R expression disrupts cardiac development
To complement pharmacological studies assessing the
role of S1P1R during heart development, we examined
the morphology of S1P1R-/- embryonic hearts at two
embryonic stages E10.5 and E12.5. Examination of E10.5
hearts was chosen for two reasons. First, cardiac cushion
development is well underway at this stage and we could
thus compare in vivo cushion development with that
observed in our in vitro AV canal culture system. Second,
E10.5 embryos do not show signs of hemorrhage. E12.5
was selected because S1P1R-/- embryos are alive at this
age and are represented at the correct Mendelian ratio,
where as S1P1R-/- embryos begin to die at E13.5.
Although E12.5 S1P1R-/- embryos have some intra-
embryonic bleeding and their limbs are underdeveloped,
their overall size is similar to S1P1R+/+ littermates [20].
E10.5 S1P1R-/- embryos were not significantly smaller
than S1P1R+/+ or S1P1R+/- littermates. The crown-rump
(CR) lengths of E10.5 embryos were S1P1R+/+ 4.63 mm ±
0.38 mm, N = 5; S1P1R+/- 4.82 ± 0.22 mm, N = 12;
S1P1R-/- 4.25 mm ± 0.33 mm, N = 7. However, the hearts
of S1P1R-/- embryos had reduced myocardial tissue, with
ventricular myocardial area reduced by 27% compared to
S1P1R+/+ littermates (Figure 5). The heart walls in the
S1P1R-/- primitive ventricle were thinner and the trabecu-
lae were less developed compared to S1P1R+/+ and S1P1R
+/- littermates (Figure 5). No differences in the sizes of the
outflow tract (OFT) or AV canal cushions were observed
at E10.5 (Figure 5).
No differences in embryo sizes were observed between
S1P1R genotypes at E12.5. The CR lengths of E12.5
embryos were S1P1R+/+ 8.54 mm ± 0.16 mm, N = 6;
S1P1R+/- 8.64 mm ± 0.09 mm, N = 19; S1P1R-/- 8.38
mm ± 0.25 mm, N = 10. S1P1R-/- hearts, though, were
smaller with a shortened long axis and reduced overall
ventricular tissue (Figures. 6, 7). The average length of
S1P1R-/- hearts was 21% less than S1P1R+/+ hearts
when measured from the AV canal to the apex of the
heart (Figure 6). S1P1R-/- hearts had 21% less ventricu-
lar myocardial tissue than S1P1R+/+ hearts (Figure 6).
Cardiac cushions in E12.5 hearts did not show differ-
ences in size among the different S1P1R genotypes
(Figure 6).
To assess the myocardial structure of S1P1R-/- hearts,
immunohistochemistry with antibodies against the myo-
cardial marker sarcomeric a-actin was performed. This
analysis revealed disrupted morphology in E12.5 S1P1R-/-
hearts, they displayed a thickened and more disorganized
ventricular myocardial wall and trabeculae compared to
the tightly compacted ventricular wall and well-organized
trabeculae of S1P1R+/+ hearts (Figure 7). In addition, the
apexes of the S1P1R-/- hearts were blunted and rounded
as compared to S1P1R+/+ hearts, which exhibited a V
shape that tapers to the apex (Figure 7).
To characterize the cardiac cushion tissue and extra-
cellular matrix (ECM) structure in S1P1R-/- hearts, we
Figure 5 Loss of S1P1R inhibits cardiac growth and morphology
at E10.5. E10.5 embryos were fixed, sectioned saggitally and stained
with H&E. (A) S1P1R+/+ hearts exhibits normal morphology. (B)
S1P1R-/- hearts demonstrate reduced myocardial tissue with a thin
ventricular wall. (C) The average area of the myocardium at the level
of the cardiac cushion, as well as the average area of the
atrioventricular (AV) canal cushions and outflow tract (OFT) cushions,
were determined. V = ventricle. S1P1R+/+, N = 4; S1P1R+/-, N = 5;
S1P1R-/-, N = 3, *P ≤ 0.02. Scale bar equals 500 μm.
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Page 6 of 12performed immunohistochemistry against fibronectin
(FN), an important ECM component in the heart during
development. This analysis identified disruptions in the
pattern of fibronectin protein expression in the heart at
E12.5 (Figure 8). In S1P1R+/+ hearts, there was strong
staining for FN in the subepicardial layer, discrete FN
deposition in the myocardium, and strong FN deposition
in the cardiac cushions (Figure 8). In contrast, S1P1R-/-
hearts showed reduced FN expression throughout the
myocardium of the ventricular wall and trabeculae, as
well as reduced FN deposition in the cardiac cushions
(Figure 8). Although S1P1R-/- hearts displayed FN
expression in the epicardial layer, this expression revealed
a less cohesive epicardial layer with areas detached from
the underlying myocardial layer (Figure 8).
To determine if the reduced size of S1P1R-/- hearts
was due to increased cell death or decreased cell prolif-
eration, we performed TUNEL analysis or immunos-
tained for the proliferation marker phospho-histone H3.
We observed a very low rate of cell death in E12.5
hearts of all S1P1R genotypes examined. Throughout the
entire heart, including the ventricle, atrium and cardiac
cushions, there were no more than 3 TUNEL-positive
cells per section, and often there were no TUNEL-posi-
tive cells in a particular heart section. To quantitate the
amount of cell death, myocardial cells were analyzed, as
they were the most numerous cell type. The rate of cell
death as determined by TUNEL analysis in the myocar-
dium was not significantly different among the three
S1P1R genotypes. The cell death rates were S1P1R+/+
0.07% ± 0.04, N = 3; S1P1R+/- 0.07% ± 0.04, N = 3;
S1P1R-/- 0.16% ± 0.09, N = 3; (P >0.05, one-way
ANOVA). In contrast to cell death, a decrease in the
cell proliferation rate was observed in the myocardial
cells of E12.5 hearts. S1P1R-/- myocardial cells had a
reduction in cell proliferation of 33%, the rates were
S1P1R+/- 0.95% ± 0.05, N = 3, and S1P1R-/- 0.63% ±
0.08, N = 3 (P <= 0.02, two-tailed students t-Test).
Examination of S1P1R-/- embryonic hearts revealed
two distinct problems associated with the loss of S1P1R
expression. First, S1P1R-/- hearts were disproportio-
nately smaller than the rest of the embryo. Second, the
overall morphology of the hearts was disrupted at each
embryonic stage examined. The decrease in cardiac size
is in part due to the reduction in cell proliferation in
myocardial cells and not an increase in cell death. S1P
has been shown to be a potent stimulator of cell prolif-
eration, especially in cardiovascular cells [8].
The explanation for the disrupted cardiac morphology
is less clear. At E10.5 the myocardial layer was thinner
in S1P1R-/- hearts compared to S1P1R+/+ littermates.
At E12.5, S1P1R-/- hearts displayed an irregular outer
myocardial layer of uneven thickness, possibly due to
altered cell proliferation rates observed in S1P1R-/-
hearts.
Another possible explanation for the malformed myo-
cardium in S1P1R-/- hearts could be a disruption in the
epicardium. Similar defects in cardiac development have
been observed when epicardium formation was defective,
resulting in thin ventricular myocardium, disrupted com-
pact layer formation, and malformations in cardiac cush-
ion development [37]. An important component of the
epicardial layer is the extra-cellular matrix molecule
fibronectin, which is critical for the migration of epicar-
dial cells over the myocardium [38]. In addition, it was
reported that S1P stimulates FN matrix assembly and
that inhibition of sphingosine kinase 1 leads to decreased
FN expression [39,40]. This idea that altered S1P signal-
ing disrupts FN expression and leads to cardiac
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Figure 6 Loss of S1P1R inhibits cardiac growth at E12.5. (A) The
average myocardial area at the level of cardiac cushions and the
cardiac cushions were measured. S1P1R-/- hearts had less ventricular
tissue but were normal for cardiac cushion size, both AV canal and
outflow tract. S1P1R+/+, N = 5; S1P1R+/-, N = 3; S1P1R-/-, N = 4. *P
≤ 0.02. (B) The length of the heart was measured from the AV canal
cushion to the apex of the heart. S1P1R-/- hearts were shorter than
S1P1R+/+ and S1P1R+/- littermates. S1P1R+/+, N = 3; S1P1R+/-, N =
3; S1P1R-/-, N = 3. *P ≤ 0.0006.
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Page 7 of 12malformations is supported by our immunohistochemical
analysis of FN. We observed reduced levels of FN in the
cardiac cushions and throughout the myocardium of
S1P1R-/- hearts. In addition, our analysis of FN revealed
a disruption in the epicardial layer, including portions of
the layer that have delaminated from the underlying
myocardium. This disrupted epicardial layer may explain
the disorganized myocardium observed in the compact
layer of S1P1R-/- hearts; however, further analysis of the
role of S1P during epicardial development will be needed
to investigate this possibility.
Other than reduced FN expression, there are no major
differences in the cardiac cushions of S1P1R-/- and S1P1R
+/+hearts. It is difficult to directly compare the in vitro
and in vivo cardiac cushion results because the alterations
in S1P signaling are different. In vitro, the loss of S1P sig-
naling, due to a block in S1P production, results in cell
death, whereas only S1P1R signaling is lost in the in vivo
transgenic model, which results in reduced cell prolifera-
tion. In the in vivo model, it is possible that other S1P
receptors expressed in the heart may compensate for the
loss of S1P1R, which is not possible in the in vitro model
since all S1P signaling is blocked. As for the effects of S1P
and S1P1R agonists, their treatment causes increased S1P
signaling, which is opposite to the in vivo model where
S1P1R signaling is lost. These opposite effects on S1P sig-
naling may explain why the in vitro system shows a dra-
matic effect on cell morphology and migration, where as
no gross morphological differences in the cardiac cushions
are observed with the in vivo model.
S1P1R-/- embryos die at E14.5 due to a failure in the
maturation of the vasculature, which leads to hemorrha-
ging and death [15]. These previously reported data sup-
port the idea that effects on cardiac development
observed in the S1P1R-/- embryos could be secondary to
vascular defects. However, data in this report indicates
that loss of S1P1R-/- expression leads to direct effects
on cardiac growth and morphogenesis at these early
stages, specifically: 1) S1P1Rs are highly expressed in the
heart, 2) altered S1P signaling in isolated heart tissue
causes cell morphology and cell migration defects, 3)
S1P1R-/- embryos are alive and not smaller than S1P1R
+/+ littermates, 4) S1P1R-/- hearts are smaller than
S1P1R+/+ littermates, 5) S1P1R-/- myocardial cells have
reduced cell proliferation rates compared to S1P1R+/-
myocardial cells in vivo. 6) S1P1R-/- hearts have reduced
FN deposition in the heart compared to S1P1R+/+
littermates.
Figure 7 Loss of S1P1R causes altered cardiac morphology at E12.5. Saggital heart sections were immunostained for sarcomeric a-actin
(green) and counterstained with propidium iodide (red) to mark the nuclei. (A, B, C) E12.5 S1P1R+/+ heart exhibits normal morphology. (D, E, F)
E12.5 S1P1R-/- heart demonstrates disrupted morphology, including rounded apex, reduced ventricular tissue and disorganized compact layer
and trabeculae. (A, D) 100X, (B, E) 200X, and (C, F) 400X magnification. Scale Bar = 200 μm. V = ventricle, A = atrium, * = AV canal cushion.
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Page 8 of 12Conclusions
Our findings identify S1P1Rs as the predominate media-
tors of S1P action in developing AV canal tissue and
demonstrate that loss of S1P1Rs disrupt normal cardiac
development. These findingsi d e n t i f yS 1 Pa c t i n gv i a
S1P1Rs as an important mediator of cardiac develop-
ment through the regulation of cell morphology, cell
proliferation and fibronectin expression. Identifying fac-
tors that influence cardiac development is critical for
increasing our understanding of the pathogenesis of
congenital heart disease, with the ultimate goal of
decreasing disease morbidity and mortality. Further stu-
dies are required to determine whether factors that alter
S1P levels during embryonic development can also influ-
ence cardiac development.
Methods
Animals
All experiments conducted on animals for this report
were first approved by the Institutional Animal Care
and Use Committee (IACUC) of Yale University. C57Bl/
6 mice were obtained from Charles River Laboratories
(Wilmington, MA). The S1P1R knockout mouse line
was obtained from Dr. Proia at National Institute of
Diabetes and Digestive and Kidney Diseases, National
Institutes of Health, and has been described [15,20]. All
S1P1R knockout mice and embryos were genotyped by
PCR analysis of genomic DNA isolated from tail tips or
yolk sac tissue. Genomic DNA was isolated with a
DNeasy Tissue Kit (Qiagen, Valencia, CA), and PCR was
performed, as described [15,20]. S1P1R+/- vs. S1P1R+/-
mice were mated so that all genotypes (S1P1R+/+,
S1P1R+/-, and S1P1R-/-) were produced. Timed matings
were used to obtain the appropriate staged embryos.
E0.5 was designated as the day a vaginal plug was
observed.
Chemicals
Sphingosine-1-phosphate (S1P; Sigma-Aldrich, St. Louis,
MO) was dissolved in 100% methanol to 5.25 mM and
diluted to 250 μM in 0.1% fatty acid-free bovine serum
albumin (FAF-BSA; Sigma). FTY720, KRP203, and
CAY10444 (Cayman Chemical, Ann Arbor, MI) were
resuspended in dimethyl formamide and diluted with
0.1% FAF-BSA.
Real-Time PCR
E9.5 and E12.5 hearts and embryos were collected under
a dissecting microscope, as described [10]. Tissue was
rinsed in PBS, placed in a 1.5 ml microcentrifuge tube,
Figure 8 Reduced fibronectin deposition observed in S1P1R-/- hearts. E12.5 transverse embryo sections were immunostained with an anti-
fibronectin antibody followed by a secondary antibody conjugated to Alexa Fluor 488 (green), and counterstained with propidium iodide (red).
(A, B, C) S1P1R+/+ hearts demonstrate strong FN staining in the outflow tract (OFT) and atrioventricular canal (AV) cardiac cushions, epicardial
layer (arrow), and throughout the ventricular (V) myocardium and trabeculae (*). (D, E, F) FN expression in the epicardial layer (arrow) of S1P1R-/-
hearts revealed a more disorganized layer compared to S1P1R+/+ hearts. In addition, the amount of FN deposited surrounding myocardial and
trabecular cells was reduced compared to S1P1R+/+ hearts. At = atrium. A, D scale bar = 200 μm; B, C, E, F scale bar = 100 μm.
Poulsen et al. BMC Developmental Biology 2011, 11:37
http://www.biomedcentral.com/1471-213X/11/37
Page 9 of 12flash frozen in liquid nitrogen, and stored at -80°C until
RNA isolation. RNA isolation of both hearts (10-12
hearts were pooled per isolation) and embryos without
hearts (single embryo per isolation) was performed with
the RNeasy Plus Kit (Qiagen) as described [10]. Three
separate pools of hearts and three separate embryos
with out hearts were used for a biological N of 3. The
experiments were carried out in the investigators lab.
RNA was eluted in 50 μlo fR N a s e - f r e ew a t e r .1μgo f
RNA was reversed transcribed as reported [10]. Each
real-time PCR reaction contains IQ SYBR Green Super
Mix (Bio-Rad, Hercules, CA), 50 ng cDNA, and 0.5 μM
of each primer in a 20 μl reaction volume. PCR was per-
formed at 55°C for annealing with an Opticon 2 DNA
Engine PCR machine (Bio-Rad). All primers were
designed against mouse sequence including b-actin as a
control gene (forward 5’-TGTTTGAGACCTTCAA-
CACC-3’,r e v e r s e5 ’-TAGGAGCCAGAGCAGTAATC-
3’). Murine S1P receptor primers for real-time PCR
were obtained from SA Bioscience (Frederick, MD).
Each real-time PCR experiment was performed in tripli-
cate for each of the biological samples of RNA collected.
PCRs were analyzed by mean normalized expression,
with b-actin as the control gene. DNA contamination
was assessed by a no RT control.
AV Canal Cultures
AV canal cultures were prepared from E9.5 hearts from
C57BL/6 mice, as reported [10,41]. Each culture con-
tained three AV canal explants that were treated with
drugs at 2 and 24 hours in culture, and stopped after 48
hours, as described [10]. After 48 hours, AV canal cul-
tures were photographed by phase contrast microscopy
using an Olympus IX70 inverted microscope. Images
were used to measure cellular outgrowth from the
explants with computer software, as described [10].
Mesenchymal cells in the collagen gels were counted for
each explant, as reported [10].
Explants were fixed in 4% paraformaldehyde (PFA)
and prepared for immunostaining as described [10]. The
actin cytoskeleton was examined with phalloidin conju-
gated to Alexa Fluor 488 (Molecular Probes, Eugene,
Oregon) and counterstained with propidium iodide to
highlight the nuclei, as described [10].
The level of apoptosis in AV canal cultures was
assessed 48 hours after drug treatment with the LIVE/
DEAD Viability/Ctotoxicity kit (Molecular Probes),
according to the manufacturer’s instructions and as
reported [10].
Embryo and Cardiac Morphological Analysis
Gross morphology of the embryos was examined by
light microscopy and digital images were captured.
Gross abnormalities were recorded upon collection of
the embryos and crown-rump lengths were determined
from the digital images. Embryos were fixed in 4% PFA
overnight at 4°C. Embryos were embedded in paraffin as
described [42], sectioned, and stained with hematoxylin
and eosin (H&E)[10]. H&E stained tissue sections were
used to assess cardiac cushion area, as described [43].
Cardiac cushion ECM was evaluated by immunostaining
with antibodies against fibronectin as detailed [42]. H&E
sections were used to assess myocardial area and wall
thickness, as described [43]. The axial length of the
heart from the AV canal cushion to the apex of the
heart was determined using Image-Pro Plus software
(Media Cybernetics, Silver Springs, MD). Paraffin sec-
tions were immunostained with antisera to sarcomeric
a-actin (Sigma-Aldrich), as described [42], in order to
highlight myocardial wall structure, trabeculation, and
septation. Sarcomeric a-actin staining was examined
with an Olympus Fluoview laser scanning confocal
microscope, as reported [10].
Paraffin sections, of E12.5 embryos (C57Bl/6) fixed in
4% PFA, were immunostained with antisera to S1P1R
(EDG-1 (H-60) sc-25489, Santa Cruz Bioechnology Inc.,
Santa Cruz, CA). The Vectastain Elite ABC Kit (Vector
Laboratories, Burlingame, CA) was used in combination
with the Vector SG substrate kit (Vector Laboratories)
according to the manufacturer’s specifications to visualize
S1P1R protein expression. The resulting color reaction
caused a blue-gray precipitate to form where S1P1Rw a s
expressed. Sections were also counterstained with
nuclear fast red (Vector Laboratories) to mark the nuclei
of each cell. As a control for S1P1R antibody staining,
normal rabbit IgG (Santa Cruz) was used at the same
concentration as the primary antibody for S1P1R, which
was 2 μg/ml.
TUNEL and Cell Proliferation Analysis
Embryonic heart sections at E12.5 were assayed for cell
d e a t hw i t ht h eI nS i t uC e l lD e a t hD e t e c t i o nk i t( R o c h e ,
Mannheim, Germany) according to the manufacturer’s
instructions and as reported [10,42]. The number of
apoptotic and total number of cells were counted in four
sections of ventricular myocardium per heart, between
2000 and 3500 cells were counted per heart. Three hearts
per S1P1R genotype were analyzed. The percentage of
TUNEL positive cells divided by the total number of
myocardial cells was the rate of cell death.
Cell proliferation in embryonic myocardial cells was
determined by immunohistochemical analysis with an
anti-phospho-histone H3 (Ser-10) antibody (Millipore
Corp., Billerica, MA). Embryos were fixed and sectioned,
as described above. In addition to the anti-phospho-his-
tone H3 antibody, an anti-sarcomeric a-actin primary
antibody was used to label myocardial cells in the
embryonic hearts. After primary antibody incubation,
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Page 10 of 12sections were incubated with secondary antibodies, goat
anti-rabbit IgG Alexa Fluor 546 (for H3) and goat anti-
mouse IgM Alexa Fluor 488 (for actin; Molecular
Probes). Nuclei were counterstained with 4’,6-Diami-
dino-2-phenylindole dihydrochloride (DAPI; Sigma).
Between 8,000 and 12,000 cells were counted in the
ventricular myocardium for each embryonic heart.
Counts were taken from at least 10 sections throughout
the whole heart. The cell proliferation rate is equal to
the number of H3-positive cells divided by the total
number of cells counted (DAPI-positive) per heart.
Three hearts per S1P1R genotype were analyzed.
Statistical Analysis
Data are presented as mean +/- SEM. Analyses were
performed using Microsoft Excel (Microsoft, Redmond,
WA) and GraphPad Prism (GraphPad Software, San
Diego, CA). Statistical comparisons between groups
were performed by Student t Tests (two sample assum-
ing equal variances) and one-way ANOVA with Bonfer-
roni post test. P < 0.05 was considered to indicate
statistical significance.
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